Production of a panel of monoclonal antibodies, specific for PSA, for the diagnosis of prostate cancer using IRMA or RIA

Immunoradiometric assay and Enzyme linked immunosorbent assay were developed for measurement of total-PSA in human serum. Similar assays for free-PSA are also under final optimization and validation. In order to develop in-house assays monoclonal antibodies were raised against PSA at our laboratory, screened and selected. MAbs with good specificity and suitability for use in both total and free PSA IRMAs could be identified. The developed assays exhibited equimolar response towards the different forms of PSA and compared well with commercial t-PSA kits. Using one of our in-house MAbs, immunopurification of PSA from seminal plasma could be achieved and PSA of ∼91% purity could be obtained. (author)